01 — At a Glance
The Pharma Giant That Just Turned Serious About Specialty Care
- 52-Week High / Low₹2,370 / ₹1,774
- Q3 FY26 Revenue₹7,168 Cr
- Q3 FY26 PAT₹1,181 Cr
- Q3 EPS (₹)₹25.73
- Annualised EPS (9M Avg×4)₹102.2
- Book Value₹430
- Price to Book5.45x
- Dividend Yield0.51%
- Debt / Equity0.32x
- Return (6 months)+20.4%
Auditor’s Opening Note: Lupin closed Q3 FY26 with ₹7,168 crore revenue (+24.3% YoY), ₹1,181 crore PAT (+75.99% YoY), and a profit jump of 76%. EBITDA margin expanded to 31.1% — call it the highest the company has ever been. Meanwhile, the US business touched USD 350 million quarterly (highest-ever), Pegfilgrastim (biosimilar) just got FDA approval, and a ₹2,000 crore ophthalmic company acquisition is about to close. The P/E of 21.5x is justified if they execute specialty right. The P/E becomes expensive if they don’t.
02 — Introduction
The Generic Drugmaker That Wants to Be a Specialty Pharma Legend
Once upon a time, Lupin was a name that appeared on generic blister packs and government tender lists. Respectable. Profitable. Boring. The kind of pharmaceutical company that sells amoxicillin at ₹2 per tablet and calls it innovation.
No longer. Management’s Q3 concall sounded like someone who finally got bored with the generic game and decided to play specialty poker. Biosimilars launching. Injectables ramping. Ophthalmic footprint expanding into Europe. GLP-1 diabetes plays (yes, the obesity drug thing). And a pivot to 505(b)(2) complex generics that actually command pricing power. The company is still selling generics in India and the US — it’s not going anywhere — but the future is being architected in specialty clinics, oncology units, and data centre cooling facilities (seriously, they mentioned that).
Q3 FY26 was the inflection point. The results prove it. And the stock market has finally started noticing. But here’s the question: Is Lupin about to become a growth story with real legs, or just another generic pharma company dressed up in specialty clothing with a loan on its balance sheet?
Let’s find out. With data, some sarcasm, and the kind of granular commentary that usually requires a ₹2 lakh annual subscription to actual research houses.
Concall Highlight (Feb 2026): “Highest sales ever in the US” + “exceed[ed] the record performance we had delivered last quarter” = management is literally on an adrenaline drip. This is the tone of executives who have finally seen their strategy work.
03 — Business Model: WTF Do They Even Do?
Generics (The Old Reliable). Plus Biosimilars (The New Sexy). Plus Everything In Between.
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
